AR085502A1 - Inhibidores triciclicos de quinasas utiles como agentes anticancerigenos y composiciones farmaceuticas que los contienen - Google Patents

Inhibidores triciclicos de quinasas utiles como agentes anticancerigenos y composiciones farmaceuticas que los contienen

Info

Publication number
AR085502A1
AR085502A1 ARP120100641A ARP120100641A AR085502A1 AR 085502 A1 AR085502 A1 AR 085502A1 AR P120100641 A ARP120100641 A AR P120100641A AR P120100641 A ARP120100641 A AR P120100641A AR 085502 A1 AR085502 A1 AR 085502A1
Authority
AR
Argentina
Prior art keywords
alkyl
cycloalkyl
heteroaryl
heterocycloalkyl
aryl
Prior art date
Application number
ARP120100641A
Other languages
English (en)
Spanish (es)
Inventor
Alan P Florjancic
Thomas D Penning
Yunsong Tong
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of AR085502A1 publication Critical patent/AR085502A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
ARP120100641A 2011-02-28 2012-02-28 Inhibidores triciclicos de quinasas utiles como agentes anticancerigenos y composiciones farmaceuticas que los contienen AR085502A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161447405P 2011-02-28 2011-02-28

Publications (1)

Publication Number Publication Date
AR085502A1 true AR085502A1 (es) 2013-10-09

Family

ID=46000328

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120100641A AR085502A1 (es) 2011-02-28 2012-02-28 Inhibidores triciclicos de quinasas utiles como agentes anticancerigenos y composiciones farmaceuticas que los contienen

Country Status (11)

Country Link
US (1) US8710065B2 (enExample)
EP (1) EP2681221B1 (enExample)
JP (1) JP5886326B2 (enExample)
CN (1) CN103703005A (enExample)
AR (1) AR085502A1 (enExample)
CA (1) CA2827648A1 (enExample)
ES (1) ES2587514T3 (enExample)
MX (1) MX340402B (enExample)
TW (1) TWI532742B (enExample)
UY (1) UY33925A (enExample)
WO (1) WO2012161812A1 (enExample)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
PE20190736A1 (es) 2012-06-13 2019-05-23 Incyte Holdings Corp Compuestos triciclicos sustituidos como inhibidores del receptor del factor de crecimiento de fibroblastos (fgfr)
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
KR102269032B1 (ko) 2013-04-19 2021-06-24 인사이트 홀딩스 코포레이션 Fgfr 저해제로서 이환식 헤테로사이클
JPWO2015029447A1 (ja) * 2013-08-30 2017-03-02 興和株式会社 光学活性カルビノール化合物の製造方法
GB201322602D0 (en) 2013-12-19 2014-02-05 Almac Discovery Ltd Pharmaceutical compounds
AU2015245901B2 (en) * 2014-04-10 2017-05-25 Dalhousie University Treatment of Parkinson's disease through ArfGAP1 inhibition using substituted piperazine derivatives
CN107072970B (zh) * 2014-08-29 2021-05-25 得克萨斯州大学系统董事会 用于治疗癌症和其他增殖性疾病的新的辣椒平类似物
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
ES2895769T3 (es) 2015-02-20 2022-02-22 Incyte Corp Heterociclos bicíclicos como inhibidores de FGFR
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
CA3043945A1 (en) 2016-11-16 2018-05-24 Sui Xiong Cai 8,9-dihydroimidazo[1,2-a]pyrimido[5,4-e]pyrimidin-5(6h)-ones
CN110198943B (zh) * 2017-01-23 2021-04-16 石家庄智康弘仁新药开发有限公司 作为Wee1抑制剂的1,2-二氢-3H-吡唑[3,4-d]嘧啶-3-酮衍生物
SG11201908788YA (en) 2017-03-31 2019-10-30 Seattle Genetics Inc Combinations of chk1- and wee1 - inhibitors
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
CN110914277B (zh) * 2017-07-10 2022-08-09 上海瑛派药业有限公司 咪唑并[1,2-b]嘧啶并[4,5-d]哒嗪-5(6H)-酮类化合物及其应用
JOP20200024A1 (ar) 2017-08-04 2020-02-02 Bayer Ag مركبات ثنائي هيدروكساديازينون
EP3661917B1 (en) 2017-08-04 2022-05-11 Bayer Aktiengesellschaft 6-((3-trifluoromethyl)phenyl)-4,5-dihydropyridazin-3(2h)-one derivatives as pde3a and pde3b inhibitors for treating cancer
CN107821390A (zh) * 2017-10-13 2018-03-23 南京扬子鸿利源化学品有限责任公司 一种甲基磺草酮油悬浮剂及其制备方法
WO2019085933A1 (zh) 2017-11-01 2019-05-09 南京明德新药研发股份有限公司 作为Wee1抑制剂的大环类化合物及其应用
SI3788047T1 (sl) 2018-05-04 2024-11-29 Incyte Corporation Trdne oblike inhibitorja fgfr in postopki priprave le-teh
SG11202010882XA (en) 2018-05-04 2020-11-27 Incyte Corp Salts of an fgfr inhibitor
CN108727249A (zh) * 2018-07-07 2018-11-02 台州学院 3-二氟甲基哌啶盐酸盐及其衍生物的合成方法
MX2021003531A (es) * 2018-09-27 2021-07-21 Betta Pharmaceuticals Co Ltd Inhibidor de fgfr4 y su uso.
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
US12180184B2 (en) 2018-10-26 2024-12-31 Wuxi Biocity Biopharmaceutics Co., Ltd. Pyrimidopyrazolone derivative as Wee1 inhibitor and use thereof
CA3128293A1 (en) 2019-02-01 2020-08-06 Bayer Aktiengesellschaft 1,2,4-triazin-3(2h)-one compounds for the treatment of hyperproliferative diseases
WO2020168197A1 (en) 2019-02-15 2020-08-20 Incyte Corporation Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors
WO2020180959A1 (en) 2019-03-05 2020-09-10 Incyte Corporation Pyrazolyl pyrimidinylamine compounds as cdk2 inhibitors
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
WO2020205560A1 (en) 2019-03-29 2020-10-08 Incyte Corporation Sulfonylamide compounds as cdk2 inhibitors
HRP20241008T1 (hr) 2019-04-30 2024-11-08 Wuxi Biocity Biopharmaceutics Co., Ltd. Kristalni oblik spoja inhibitora wee1 i njegova uporaba
US11447494B2 (en) 2019-05-01 2022-09-20 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
WO2020223469A1 (en) 2019-05-01 2020-11-05 Incyte Corporation N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
PH12022550361A1 (en) 2019-08-14 2023-02-27 Incyte Corp Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors
CN112442049A (zh) * 2019-09-03 2021-03-05 微境生物医药科技(上海)有限公司 作为Wee1抑制剂的嘧啶衍生物
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
PE20221905A1 (es) 2019-10-11 2022-12-23 Incyte Corp Aminas biciclicas como inhibidoras de la cdk2
US11607416B2 (en) 2019-10-14 2023-03-21 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US20240010655A1 (en) * 2019-10-16 2024-01-11 Impact Therapeutics (Shanghai), Inc Dihydroimidazo pyrimido pyrimidinone compound
WO2021113462A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Derivatives of an fgfr inhibitor
EP4069696A1 (en) 2019-12-04 2022-10-12 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
CN115698006B (zh) 2020-06-17 2024-03-29 微境生物医药科技(上海)有限公司 作为Wee-1抑制剂的吡唑并[3，4-d]嘧啶-3-酮衍生物
CN116888107A (zh) * 2021-02-19 2023-10-13 微境生物医药科技(上海)有限公司 作为Wee-1抑制剂的稠环化合物
WO2022221170A1 (en) 2021-04-12 2022-10-20 Incyte Corporation Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
JP2024515318A (ja) * 2021-04-30 2024-04-08 ウィゲン・バイオメディシン・テクノロジー・（シャンハイ）・カンパニー・リミテッド Ｗｅｅ－１阻害剤としての縮合環状化合物、その調製方法およびその使用
WO2022261159A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2022261160A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
AU2022384370A1 (en) * 2021-11-09 2024-06-13 Hangzhou Glubio Pharmaceutical Co. Ltd. Wee1 protein kinase degradation agent and use thereof
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors
CN116836184B (zh) * 2022-03-25 2025-07-25 药雅科技(上海)有限公司 Wee1激酶抑制剂的制备及其应用
WO2024199388A1 (zh) * 2023-03-29 2024-10-03 微境生物医药科技(上海)有限公司 作为myt1抑制剂的化合物
CN119039287A (zh) * 2023-05-29 2024-11-29 中国药科大学 一类四氢吡啶并嘧啶酮衍生物及其制备方法与应用
KR20250136774A (ko) * 2024-03-08 2025-09-16 보로노이 주식회사 헤테로아릴 유도체 화합물 및 이의 용도

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004261589B2 (en) 2003-07-25 2008-05-22 Novartis Ag p-38 kinase inhibitors
US20050070554A1 (en) * 2003-08-27 2005-03-31 Amgen Inc. Substituted heterocyclic compounds and methods of use
US20050250836A1 (en) * 2004-05-03 2005-11-10 Pfizer Inc Inhibitors of checkpoint kinases (Wee1 and Chk1)
AR058277A1 (es) 2005-12-09 2008-01-30 Solvay Pharm Gmbh N- sulfamoil - piperidin - amidas, composiciones farmaceuticas que las comprenden y procedimiento para su preparacion
KR101555384B1 (ko) * 2006-12-13 2015-09-23 아스카 세이야쿠 가부시키가이샤 퀴녹살린 유도체
EP2213673B1 (en) * 2007-10-23 2013-06-05 Msd K.K. Pyridone-substituted-dihydropyrazolopyrimidinone derivative
EP2303885B1 (en) 2008-06-12 2013-07-03 Merck Sharp & Dohme Corp. Process for producing bicycloaniline derivatives
WO2010067886A1 (en) * 2008-12-12 2010-06-17 Banyu Pharmaceutical Co.,Ltd. Dihydropyrimidopyrimidine derivative

Also Published As

Publication number Publication date
UY33925A (es) 2012-09-28
CN103703005A (zh) 2014-04-02
MX340402B (es) 2016-07-07
ES2587514T3 (es) 2016-10-25
US8710065B2 (en) 2014-04-29
JP2014506929A (ja) 2014-03-20
EP2681221B1 (en) 2016-05-18
CA2827648A1 (en) 2012-11-29
US20120220572A1 (en) 2012-08-30
EP2681221A1 (en) 2014-01-08
JP5886326B2 (ja) 2016-03-16
MX2013009873A (es) 2014-03-12
TWI532742B (zh) 2016-05-11
WO2012161812A1 (en) 2012-11-29
TW201247675A (en) 2012-12-01

Similar Documents

Publication Publication Date Title
AR085502A1 (es) Inhibidores triciclicos de quinasas utiles como agentes anticancerigenos y composiciones farmaceuticas que los contienen
ES2528451T3 (es) Inhibidores de esfingosina cinasa
AR107127A1 (es) Indazoles sustituidos, procedimientos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos
EA201390199A1 (ru) 2-замещенные-8-алкил-7-оксо-7,8-дигидропиридо[2,3-d]пиримидин-6-карбонитрилы и их применение
AR076794A1 (es) Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo [2,3-d]pirimidinas y pirrol-3-il-pirrolo [2,3-d ]pirimidinas como inhibidores de la quinasa janus y composiciones farmaceuticas que los contienen
AR097431A1 (es) Compuestos de carboxamida de furo y tienopiridina útiles como inhibidores de quinasas pim
BR112014032338A2 (pt) cristais de sal
CL2016001537A1 (es) Inhibidores de syk
PE20190811A1 (es) Derivados de pirazolopirimidinas como inhibidor de quinasa
MX2019003605A (es) Formas solidas de un inhibidor de cdk4/6 selectivo.
CL2014002220A1 (es) Compuesto 1-(3,3-dimetilbutil)-3-(2-fluoro-4-metil-5-(7-metil-2-(metilamino)pirido[2,3-d]pirimidin-6-il)fenil)urea, inhibidor de la cinasa raf; forma cristalina del compuesto; composicion farmaceutica que lo comprende; y metodo para tratar el cancer.
SMT201500200B (it) Derivati di imidazo[1,2-a]piridina come inibitori delle chinasi fgfr per l'uso in terapia
CL2012002318A1 (es) Compuestos derivados de tieno [2,3-d]pirimidina, inhibidores de quinasa mnk1 y mnk2; composición farmaceutica; que los comprende; y su uso en el tratamiento de enfermedades metabolicas, hematopoyeticas, neurodegenerativas, renales, inflamatorias y cancer.
MA32405B1 (fr) SELS DE 2-FLUORO-N-MÉTHYL-4-[7-(QUINOLÉIN-6-YL-MÉTHYL)- IMIDAZO[1,2-B][1,2,4]TRIAZIN-2-YL]BENZAMIDE ET PROCÉDÉS ASSOCIÉS à LEUR PRÉPARATION
CL2015002386A1 (es) Nuevos octahidro-pirrolo[3,4-c)-pirrol y -piridina-fenilo.
AR070535A1 (es) Compuestos inhibidores de raf y metodos para usarlos
CO6801740A2 (es) Inhibidores de quinasa relacionados con pirrolo[2,3-d]pirimidina tropomiosina
AR088029A1 (es) Compuestos de pirimidina sustituidos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento del dolor, accidentes cerebrovasculares, epilepsia y otras enfermedades del sistema nervioso central
CL2013002063A1 (es) Compuestos derivados de pirrolo(piridina, pirimidina o pirazina), inhibidores de serina/trionina cinasa; composicion farmaceutica que los comprende; y su uso en el tratamiento del cancer, infecciones inflamaciones y enfermedades autoinmune.
CL2014000343A1 (es) Procedimientos de preparacion de compuesto polimorfico derivado de pirazolo[3,4-d]pirimidina; sal del compuesto; composicion farmaceutica que lo comprende y su uso en el tratamiento de un trastorno asociado a mtor.
IL230511B (en) (s)-4-(8-amino-3-(1-but-2-ynoyl-pyrrolidin-2-yl)imidazo[5,1-a]pyrazin-1-yl)-n-(pyridin-2- l) Benzamide as a btk inhibitor
DK3808749T3 (da) Pyrazolo[1,5-a]pyrimidiner, der er nyttige som inhibitorer af atr-kinase til behandling af kræftsygdomme
MD20140084A2 (en) New indolizine derivatives, method for preparing same and pharmaceutical compositions containing same
MX381849B (es) Compuestos a base de pirazol[1,5-a]pirimidina, composiciones que los comprenden, y métodos para su uso.
NI201400101A (es) Inhibidores de cinasa de fosfoinositida 3 cristalina

Legal Events

Date Code Title Description
FB Suspension of granting procedure